HIGHLIGHTS
- who: Chuanliang Cui from the National Cancer Institute Common Terminology Criteria for Adverse Events ADA have published the article: Safety and efficacy of Pucotenlimab (HX008) - a Humanized Immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study, in the Journal: (JOURNAL) of November/08,/2017
- what: The authors report the safety and efficacy of Pucotenlimab in the Chinese population with locally advanced or metastatic melanoma who had failed the standard treatment (chemotherapy, targeted therapy, interferon, IL-2, et_al). Besides, no new types of TRAEs appeared in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.